What is NextPoint Therapeutics?
NextPoint Therapeutics is a biopharmaceutical company dedicated to advancing immuno-oncology through its pioneering research on the HHLA2 axis, also recognized as B7-H7. The company's innovative strategy merges fundamental scientific discoveries with a targeted clinical biomarker approach. This integration aims to introduce a novel class of monotherapies designed for patients unresponsive to existing PD-1/L1 inhibitors. Furthermore, NextPoint is developing therapeutic modalities that leverage the unique upregulation of HHLA2 in cancerous cells as a focal point for tumor-targeting treatments. A team of experienced drug developers, collaborating with distinguished scientific founders, is spearheading the creation of a new era in precision immuno-oncology.
How much funding has NextPoint Therapeutics raised?
NextPoint Therapeutics has raised a total of $122.5M across 2 funding rounds:
Series B
$80M
Series B
$42.5M
Series B (2023): $80M with participation from Invus, Sanofi Ventures, Bayer, Sixty Degree Capital, and Catalio Capital Management
Series B (2024): $42.5M led by Arkin Holdings and Catalio Capital Management
Key Investors in NextPoint Therapeutics
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofi's business footprint, and digital health solutions. Find out more: www.sanofiventures.com.
Arkin Holdings
Arkin Capital is a prominent multi-asset manager that oversees over 2 billion in assets across various sectors, including health, technology, equity, and real estate. The firm excels in making strategic investments through its specialized arms: Arkin Health for healthcare innovations, Arkin Tech for technology startups, Arkin Equity for private equity, and Arkin Real Estate for global property opportunities. Arkin Capital primarily targets early to late-stage companies and diversified investment avenues, aiming to accelerate growth and deliver impactful solutions. Its diverse portfolio includes significant investments in biotech, digital health, and sustainable energy, catering to a broad range of investors and market opportunities.
What's next for NextPoint Therapeutics?
The substantial enterprise-level funding and recent strategic investment position NextPoint Therapeutics for accelerated growth and development. This capital infusion is expected to fuel the advancement of its novel immuno-oncology pipeline, particularly its work on the HHLA2 axis. The company's focus on precision medicine and its biomarker-driven strategy suggest a clear path toward clinical validation and potential commercialization. Future endeavors will likely involve expanding clinical trials, further refining therapeutic modalities, and potentially forging strategic partnerships to broaden market reach. The company's trajectory indicates a strong commitment to addressing unmet needs in cancer treatment for patients who do not respond to current standard-of-care therapies.
See full NextPoint Therapeutics company page
